about
Modulation of host lipid metabolism by hepatitis C virus: Role of new therapiesAssessing cardiovascular risk in hepatitis C: An unmet needReview article: HCV genotype 3 – the new treatment challengeAssociation between vitamin D and hepatitis C virus infection: a meta-analysisHepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failureEffect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host TargetsHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsElafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver diseaseEpigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field.Community-acquired pneumonia during the first post-pandemic influenza season: a prospective, multicentre cohort study.Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment.Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should doEffectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.Irisin, a link among fatty liver disease, physical inactivity and insulin resistance.Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study.HAVCR1 gene haplotypes and infection by different viral hepatitis C virus genotypesA Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish PatientsHepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients.Pharmacotherapy of hepatic encephalopathy in cirrhosis.Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management.Experimental models for hepatic encephalopathy.Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations.Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin.Evolution of the incidence of inflammatory bowel disease in Southern Spain.Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3.Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.Role of assessing liver fibrosis in management of chronic hepatitis C virus infection.Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats.Treatment of NAFLD with diet, physical activity and exercise.Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients.Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.FibroGENE: A gene-based model for staging liver fibrosis.
P50
Q26782009-B04D7D2C-62E6-4C72-9385-2FC55289E83FQ26784258-10A2FAC3-6763-4E05-AB49-DC9F98BE88EAQ26864571-B2C7C762-4A5F-4BE1-9949-EE7E6191B7FBQ26866361-9870FCAF-F4A2-410C-BCCE-2ABE1C93213AQ26992036-4B714B3B-4402-4A27-96D8-8C98225D85ABQ27468855-A64138DE-5ABD-4AC3-BF3C-F5970F40E93CQ28652352-AB51460D-3899-4E8C-973A-4ED59E84C97FQ30277347-D4D2A93C-3934-44DC-8260-233149ED43F6Q30376231-27C6688E-5E67-49E1-B0F7-F6089D5C8D1BQ30400120-EB448D1D-9C21-4F08-AD7C-4E5DBDAFE99BQ30431627-9DB28C60-A828-41D5-899F-8DEE6E854316Q33350754-DD1A1588-8610-4C67-B5ED-495B08CB0900Q33639969-5426E5A8-3A6A-459F-B6C5-FDF40A92FD6FQ33716191-554F47F0-4EF5-4E67-9621-3BE87F3CED39Q33843746-6D7C120F-E637-41C3-B4AE-9E9781826BDCQ34835301-3C5AE38D-171E-472C-9E1A-6B8A184EC24DQ35197060-74A71D43-B885-41E9-BED9-86737321B5E1Q35591160-5CFEE9E5-0239-4579-B386-01935CFF2AC5Q35739135-C084FDEC-8258-4235-BC22-513A2AF8219EQ35962849-8124FE80-BDA8-4C30-BD19-1E36DE903D84Q37208092-DDF23E30-E37D-460C-A3B7-166B5CE63DFBQ37317444-32CE4B65-993A-4EFC-B093-BBB49D630A16Q37330452-6588FB6B-967D-429A-9DAF-731AEBCD1F7FQ37729173-86597C81-AE84-49FE-981F-810B5C0E7992Q37749390-7017A090-8DE1-4BBB-A2EB-331FB98A7A18Q37952860-D5F49DC3-5536-401E-8F99-47A6ED45563EQ38122536-140600AA-CBB3-4011-BA4F-3BA5474232A9Q38519928-DDB62826-AE1F-4856-B329-B501589F8FDFQ38641635-1001CB73-787D-4D67-BDC7-21BCD7212B3EQ38645611-892C3458-ED51-4408-8D74-35DF39E7529BQ38911612-A2BE3F25-A201-403D-80A0-FA7A3EC1A40CQ38966177-29B2ACC7-5DF2-4ED1-824E-63569F614BDFQ39146320-B9E14418-AE8F-4DD9-9BC7-471C68602042Q39253129-7F86E3E9-1274-41F8-8751-B4B67D1A120AQ39331043-59C4CC2A-F36D-40E0-82C3-0819C51F97D3Q39945625-0F6C1E05-1AFF-40D4-838E-A99A5DDDF91EQ40171515-03031FE3-12C1-4F2C-BAFA-7BA95FE6D44FQ40227111-65A89244-036C-433E-9DDA-5A86D9717B41Q40258100-879D09ED-C91F-4907-A79E-1D4C6F6FE7AAQ40291661-F4CD9D48-A645-4994-BA27-5B87F24E6B00
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Manuel Romero-Gomez
@ast
Manuel Romero-Gomez
@en
Manuel Romero-Gomez
@es
Manuel Romero-Gomez
@nl
type
label
Manuel Romero-Gomez
@ast
Manuel Romero-Gomez
@en
Manuel Romero-Gomez
@es
Manuel Romero-Gomez
@nl
prefLabel
Manuel Romero-Gomez
@ast
Manuel Romero-Gomez
@en
Manuel Romero-Gomez
@es
Manuel Romero-Gomez
@nl
P106
P21
P31
P496
0000-0001-8494-8947